Literature DB >> 25033067

Hyperglycemia and insulin resistance in cardiac arrest patients treated with moderate hypothermia.

Matthew D Ettleson1, Vanessa Arguello, Amisha Wallia, Lester Arguelles, Richard A Bernstein, Mark E Molitch.   

Abstract

CONTEXT: It is unknown whether the hyperglycemia that follows cardiac arrest and during therapeutic hypothermia (TH) is due to the arrest or the TH, whether it is associated with adverse outcomes, or whether its treatment affects outcomes.
OBJECTIVE: The objective of the study was to determine the effects of TH on the blood glucose (BG) levels in postcardiac arrest patients and the effects of hyperglycemia on mortality.
DESIGN: This was a chart review of 62 patients undergoing TH after cardiac arrest between September 2005 and April 2008. BG levels from 72 hours before the arrest to 48 hours after TH and iv insulin infusion rates were analyzed and correlated with survival to discharge from hospital.
SETTING: The study was conducted at a tertiary, university referral center. PATIENTS: PATIENTS undergoing TH after cardiac arrest participated in the study.
INTERVENTIONS: TH consisted of cooling as rapidly as possible to 33°C, holding that temperature for 24 hours, and then controlled rewarming to 37°C over 8 or 16 hours. Hyperglycemia was managed with iv insulin drip protocols. MAIN OUTCOME MEASURE: The relationship of cardiac arrest and hypothermia to hyperglycemia, with a key secondary outcome being the relationship of hyperglycemia to survival to discharge, was measured.
RESULTS: Analysis of glucose patterns showed no independent effect of TH on BG levels. Mean BG levels between cardiac arrest and the initiation of hypothermia were higher in nonsurvivors (253 ± 112 mg/dL, n = 48) than in survivors (192 ± 69 mg/dL, n = 24, P = .016). BG, insulin infusion rates, and insulin resistance during hypothermia, during rewarming, and 24-48 hours after hypothermia were not significantly different between the 2 groups.
CONCLUSIONS: In patients treated with TH, the TH had no independent effect on BG levels. Mortality was associated with increased BG levels after cardiac arrest but before initiation of TH or an insulin drip. Likely, it is the severity of stress from the cardiac arrest that causes the hyperglycemia in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25033067     DOI: 10.1210/jc.2014-1449

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  The Relationship Between the Decreased Rate of Initial Blood Glucose and Neurologic Outcomes in Survivors of Out-of-Hospital Cardiac Arrest Receiving Therapeutic Hypothermia.

Authors:  Jae-Hyug Woo; Yong Su Lim; Hyuk Jun Yang; Sung Youl Hyun; Jin Seong Cho; Jin Joo Kim; Gun Lee
Journal:  Neurocrit Care       Date:  2017-06       Impact factor: 3.210

Review 2.  The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society.

Authors:  Lori Kennedy Madden; Michelle Hill; Teresa L May; Theresa Human; Mary McKenna Guanci; Judith Jacobi; Melissa V Moreda; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

3.  Precise Control of Target Temperature Using N6-Cyclohexyladenosine and Real-Time Control of Surface Temperature.

Authors:  Bernard W Laughlin; Isaac R Bailey; Sarah A Rice; Zeinab Barati; Lori K Bogren; Kelly L Drew
Journal:  Ther Hypothermia Temp Manag       Date:  2018-02-26       Impact factor: 1.286

4.  Variability in Glycemic Control with Temperature Transitions during Therapeutic Hypothermia.

Authors:  Krystal K Haase; Jennifer L Grelle; Faisal A Khasawneh; Chiamaka Ike
Journal:  Crit Care Res Pract       Date:  2017-09-18

Review 5.  Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps.

Authors:  Amisha Wallia; Grace Prince; Emilie Touma; Malek El Muayed; Jane Jeffrie Seley
Journal:  Curr Diab Rep       Date:  2020-11-26       Impact factor: 4.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.